Engineered cascade components and cascade complexes

Inventors

Cameron, Peter Sean • Gradia, Scott David • Klompe, Sanne Eveline • Sternberg, Samuel Henry • Thompson, Matthew Scott

Assignees

Caribou Biosciences Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12227776-B2

Patent

Publication Date

2025-02-18

Expiration Date


Abstract

The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.

Core Innovation

The invention relates to an engineered Type I CRISPR-Cas effector composition that includes a Type I CRISPR-Cas subunit protein, a Type I guide polynucleotide, and an engineered Type I CRISPR mCas3 protein selected from Pseudomonas sp. S-6-2 mCas3 proteins D448A mCas3, D75A mCas3, and D448A D75A mCas3. The described composition is framed as a genome editing system using Type I CRISPR-Cas effector complexes.

The disclosure further encompasses engineered Cascade subunit modifications and fused or linked Cas subunit configurations. It describes Cas subunit fusion proteins, circularly permuted Cas7 (cpCas7), covalent linker arrangements between mCas3 and the Type I CRISPR-Cas subunit protein, and fused nucleases including FokI fused to Cas8. Additional functional domains or enzymes are fused to Type I subunits, including Cse2-Cse2 fusions and deaminase/activation fusions.

The content also describes recruiting Cascade subunits to Type II dCas9 complexes using engineered Type II guide RNAs that contain Type I repeat stems. Across further examples, the document describes identification and screening of Type I Cas genes and crRNAs, testing guide backbone tolerance, PAM sequences and PAM promiscuity, HDR with donor templates, base editing via deaminase fusions, transcription activation/repression via Cascade fusions, substrate-channel engineering, and genome editing-related control features for Cas3 activity and deletion length using Cas3 mutations and protein roadblocks, including paired nicking and deletion control using ATPase-deficient mCas3 variants.

Claims Coverage

The provided claim coverage centers on one engineered Type I CRISPR-Cas effector composition with three core components. The inventive features are the selected engineered mCas3 variants and dependent refinements for covalent linkage and Type I CRISPR-Cas subunit selection.

Engineered Type I CRISPR-Cas effector composition with selected Pseudomonas S-6-2 engineered mCas3 variants

An engineered Type I CRISPR-Cas effector composition comprising a Type I CRISPR-Cas subunit protein, a Type I guide polynucleotide, and an engineered Type I CRISPR mCas3 protein selected from the group consisting of Pseudomonas sp. S-6-2 mCas3 proteins D448A mCas3, D75A mCas3, and D448A D75A mCas3.

Engineered mCas3 with covalent linker to the Type I CRISPR-Cas subunit

The engineered Type I CRISPR-Cas effector composition wherein the engineered mCas3 protein and the Type I CRISPR-Cas subunit protein are covalently connected by a linker polypeptide.

Selected Type I CRISPR-Cas subunit protein set

The engineered Type I CRISPR-Cas effector composition wherein the Type I CRISPR-Cas subunit protein is selected from Cas8, Cas5, and Cas7.

The claimed coverage centers on an engineered Type I CRISPR-Cas effector composition that couples a Type I guide polynucleotide with a Type I CRISPR-Cas subunit protein and a specifically selected Pseudomonas sp. S-6-2 engineered mCas3 variant, with further narrowing by covalent linker placement and selection of the Type I CRISPR-Cas subunit protein from Cas8, Cas5, and Cas7.

Stated Advantages

The disclosed fused subunits assemble into Cascade complexes with similar composition and support target DNA binding and cleavage.

Documented Applications

Genome editing.

Target DNA binding and cleavage.

Recruiting Cascade subunits to Type II dCas9 complexes using engineered Type II guide RNAs that contain Type I repeat stems.

Editing human iPSCs at immune loci including TRAC, B2M, and PDCD1, including CAR knock-in via donor polynucleotides and homologous recombination (knock-in).

Differentiation after CAR knock-in to CAR-T/CAR-NK or dendritic/T/NK lineages.

Selection/screening of edited lymphocytes, including FACS and deep sequencing concepts.

Use of engineered Class 1 Type I CRISPR compositions and illustrative experiments addressing genome editing and DNA cleavage.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.